MEETING CANCELLED: Advances in Cancer Immunotherapy

Organizer(s): Antoni Ribas, W. Nicholas Haining and Priti Hegde

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by Bayer AG, BioLegend, Inc., Compass Therapeutics, Gilead Sciences, Inc., Genentech, Inc., Incyte Corporation, MorphoSys AG, Nektar Therapeutics, Surface Oncology and TCR² Therapeutics

For important information on the coronavirus, please click here

Summary of Meeting:

Cancer immunotherapy by blocking immune inhibitory checkpoints or engineering T cells for adoptive cell transfer is providing an unprecedented level of long-term antitumor activity in patients with several metastatic cancers. However, the majority of patients with advanced cancers still do not experience sustained clinical benefit from immunotherapy. Understanding the mechanistic basis of response and resistance to these therapies and how therapeutic approaches could best be combined will be essential to continue progress. The largest human experiment is currently being conducted with over 1,000 agents and combinations. Understanding the results to date and determining what is working and what combinations are not working will be important to refine our understanding of immunity in patients with cancer. Questions that remain unanswered include: What is the rationale for the multiple immuno-oncology (IO) combinations being tested in the clinic, how do cancers adapt and resist T cell attack, and can we better understand the tumor microenvironment, thus paving the way for new approaches to cancer therapy. New analyses of patient-derived samples provide information on adaptive and genetic resistance mechanisms to immunotherapy. The conference program will include sessions which cover topics such as new analysis techniques, methodologies, and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the immune system. Participants will leave the conference with an understanding of how the advancement of cancer biology will be influenced by a better comprehension of tumor immunology.

Meeting has been cancelled. Please call our office if you have questions at 970-262-1230 or 1-800-253-0685.

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support from these exhibitors at this conference:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.

Merck Research Laboratories

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations